Cost-effectiveness of Continuous Glucose Monitoring for Adults With Type 1 Diabetes Compared With Self-Monitoring of Blood Glucose: The DIAMOND Randomized Trial.
Wen WanM Reza SkandariAlexa MincAviva G NathanAaron WinnParmida ZareiMichael O'GradyElbert S HuangPublished in: Diabetes care (2018)
For adults with T1D using multiple insulin injections and still experiencing suboptimal glycemic control, CGM is cost-effective at the willingness-to-pay threshold of $100,000 per QALY, with improved glucose control and reductions in nonsevere hypoglycemia.